Dupilumab Emerging Insight and Market Report 2020 – Forecast to 2030 – ResearchAndMarkets.com

Dupilumab Emerging Insight and Market Report 2020 – Forecast to 2030 – ResearchAndMarkets.com




Dupilumab Emerging Insight and Market Report 2020 – Forecast to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “DUPILUMAB – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

“DUPILUMAB- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the DUPILUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor. By blocking the IL-4R alpha subunit, dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around DUPILUMAB.
  • The report contains forecasted sales for DUPILUMAB till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Chronic Spontaneous Urticaria.
  • The report also features the SWOT analysis with analyst insights and key findings of DUPILUMAB.

DUPILUMAB Analytical Perspective

In-depth DUPILUMAB Market Assessment

This report provides a detailed market assessment of DUPILUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

DUPILUMAB Clinical Assessment

The report provides the clinical trials information of DUPILUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence DUPILUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic Spontaneous Urticaria are giving market competition to DUPILUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of DUPILUMAB.
  • The in-depth analysis of the forecasted sales data of DUPILUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPILUMAB.

Key Questions Answered

  • Which company is developing DUPILUMAB along with the phase of the clinical study?
  • What is the technology utilized in the development of DUPILUMAB?
  • What is the product type, route of administration and mechanism of action of DUPILUMAB?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPILUMAB development?
  • What are the key designations that have been granted to DUPILUMAB?
  • What is the forecasted market scenario of DUPILUMAB?
  • What is the history of DUPILUMAB and what is its future?
  • What is the forecasted sales of DUPILUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to DUPILUMAB?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/bw2toy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900